or Try an Advanced Search...

    Technical Analysis for ARCH - Arch Biopartners Inc

    Grade Last Price % Change Price Change
    D 1.710 0.59% 0.010
    ARCH closed up 0.59 percent on Friday, May 10, 2024, on 4 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 28
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical ARCH trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Boomer Sell Setup Bearish Swing Setup 0.59%
    NR7 Range Contraction 0.59%
    NR7-2 Range Contraction 0.59%
    Narrow Range Bar Range Contraction 0.59%
    Wide Bands Range Expansion 0.59%
    Oversold Stochastic Weakness 0.59%
    Calm After Storm Range Contraction 0.59%
    Older End-of-Day Signals for ARCH ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 3 days ago
    Possible Inside Day 4 days ago
    Possible NR7 4 days ago
    Up 1% 4 days ago
    Fell Below Previous Day's Low 5 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ARCH Chart by TradingView
    Basic chart:

    Profile

    Arch Biopartners Inc Description

    Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies that make a medical or commercial impact. Its technology platforms include AB569, MetaBlok, Arch Inflammation, Borg and MetaMx. AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. MetaBlok is a drug candidate targeting sepsis, cancer metastasis and inflammation based diseases. Arch Inflammation is a treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. Arch Inflammation is focused on developing anti-inflammatory small molecules that target proteins in the innate immune system. Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation. MetaMx are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The Company has not generated any revenues.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Metal Health Medicine Drug Biotechnology Disease Cancer Diseases Plastic Bacteria Immunology Tumor Infection Peptide Antibiotic Immune System Inflammation Proteins Biofilm Peptides Brain Brain Tumor Chronic Kidney Infections Technology Platforms

    Is ARCH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 16 St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    Mar 18 Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
    Mar 15 University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    Mar 7 Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    Dec 21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
    Dec 18 Grant of Options to Directors and Officers
    See more ARCH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.56
    52 Week Low 0.97
    Average Volume 31,879
    200-Day Moving Average 1.594
    50-Day Moving Average 2.088
    20-Day Moving Average 1.996
    10-Day Moving Average 1.746
    Average True Range 0.090
    RSI (14) 25.93
    ADX 43.55
    +DI 16.096
    -DI 42.690
    Chandelier Exit (Long, 3 ATRs) 2.130
    Chandelier Exit (Short, 3 ATRs) 1.830
    Upper Bollinger Bands 2.551
    Lower Bollinger Band 1.441
    Percent B (%b) 0.24
    BandWidth 55.625
    MACD Line -0.138
    MACD Signal Line -0.102
    MACD Histogram -0.0366
    Fundamentals Value
    Market Cap 103.94 Million
    Num Shares 60.8 Million
    EPS -0.04
    Price-to-Earnings (P/E) Ratio -46.22
    Price-to-Sales 601.44
    Price-to-Book 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.770
    Resistance 3 (R3) 1.773 1.757 1.760
    Resistance 2 (R2) 1.757 1.741 1.755 1.757
    Resistance 1 (R1) 1.733 1.732 1.745 1.730 1.753
    Pivot Point 1.717 1.717 1.723 1.715 1.717
    Support 1 (S1) 1.693 1.701 1.705 1.690 1.667
    Support 2 (S2) 1.677 1.692 1.675 1.663
    Support 3 (S3) 1.653 1.677 1.660
    Support 4 (S4) 1.650